Vincristine combination with Ca
Amlodipine
Calcium channel blockers
Neuroblastoma
Vincristine
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
27
12
2018
accepted:
15
02
2019
pubmed:
25
3
2019
medline:
26
7
2019
entrez:
24
3
2019
Statut:
ppublish
Résumé
In this study, it was aimed to determine the effects of Amlodipine, a calcium channel blocker and vincristine (VCR) an antineoplastic, on human neuroblastomas using different doses. The cytotoxicity assays of the study were performed using the MTT method depending on time and concentration. After obtaining the mixture (up to 85% for SH-SY5Y) and sufficient branches (cortex neurons), the cells were treated with amlodipine (10 µM) and vincristine (0.5, 1 and 2 µg) at different concentrations for 24 h. MTT assay was performed by the commercially available kit (Sigma Aldrich, USA). Cells were harvested, washed and stained with PI and Annexin V, respectively, according to the manufacturer's protocol (Biovision, USA). Than analyzes were carried out. The results were quite impressive. When amlodipine (10 µM) was administered alone there was little change compared to the control. However, all doses of amlodipine (10 µM) and vincristine (0.5, 1 and 2 µg) were greater than the deaths in the doses alone (0.5, 1 and 2 µg) of vincristine alone. (P < 0.05). As a result, the combination of vincristine and amlodipine is more effective than vincristine alone in reducing the viability of cancer cells.
Identifiants
pubmed: 30903573
doi: 10.1007/s11033-019-04706-w
pii: 10.1007/s11033-019-04706-w
doi:
Substances chimiques
Antineoplastic Agents
0
Calcium Channel Blockers
0
Amlodipine
1J444QC288
Vincristine
5J49Q6B70F
Types de publication
Journal Article
Langues
eng
Pagination
2523-2528Références
N Engl J Med. 1999 Nov 4;341(19):1447-57
pubmed: 10547409
Cell. 2002 Jan 25;108(2):153-64
pubmed: 11832206
Cancer Res. 2003 Nov 1;63(21):7291-300
pubmed: 14612526
J Med Toxicol. 2008 Mar;4(1):25-9
pubmed: 18338308
Histopathology. 2008 Jul;53(1):73-80
pubmed: 18613926
Indian J Crit Care Med. 2008 Oct;12(4):190-3
pubmed: 19742263
Lancet Oncol. 2010 Jul;11(7):627-36
pubmed: 20542468
Lancet Oncol. 2010 Jul;11(7):605-6
pubmed: 20542469
Mol Pharm. 2011 Feb 7;8(1):162-75
pubmed: 21062083
Lancet Oncol. 2011 Jan;12(1):65-82
pubmed: 21123111
World J Surg. 2013 Feb;37(2):459-65
pubmed: 23135423
Neuro Endocrinol Lett. 2012;33 Suppl 3:16-24
pubmed: 23353839
Cancer Res. 1990 Jun 15;50(12):3670-4
pubmed: 2340516
Int J Cancer. 2014 May 15;134(10):2269-77
pubmed: 23784914
Int J Oncol. 2015 Jul;47(1):343-52
pubmed: 25963435
Pharmacol Rev. 2015 Oct;67(4):821-70
pubmed: 26362469
Ann Neurol. 2016 Jul;80(1):13-23
pubmed: 27043043
Clin Exp Pharmacol Physiol. 2017 Oct;44(10):971-979
pubmed: 28649767
Brain Neurosci Adv. 2018 Oct 2;2:null
pubmed: 30320224
Anticancer Res. 1985 May-Jun;5(3):265-71
pubmed: 4015040
Pflugers Arch. 1969;307(2):R25
pubmed: 5814829
J Assoc Physicians India. 1993 Oct;41(10):662-3
pubmed: 8294330
Eur J Epidemiol. 1996 Dec;12(6):563-71
pubmed: 8982615